As far as HER2 somatic mutations, they have been reported by TCGA project data in about 4% of CRC and sometimes concomitantly with HER2 amplification or alterations of other oncogenes such as RAS, BRAF, and EGFR. This evidence concerns the gene ERBB2 and colorectal carcinoma.